We are live on ! Find out more
FTXH icon

First Trust Nasdaq Pharmaceuticals ETF

34 hedge funds and large institutions have $22M invested in First Trust Nasdaq Pharmaceuticals ETF in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

31% more funds holding

Funds holding: 2634 (+8)

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

20% more capital invested

Capital invested by funds: $18.3M → $22M (+$3.69M)

1.38% more ownership

Funds ownership: 50.72%52.1% (+1.4%)

Holders
34
Holders Change
+8
Holders Change %
+30.77%
% of All Funds
0.55%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
9
Reduced
7
Closed
4
Calls
Puts
Net Calls
Net Calls Change

FTXH Hedge Fund Activity: Q4 2022 in Review

34 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q4 2022, worth a combined $22M — up 20% from $18.3M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new FTXH positions and 4 closed out — a net gain of 9 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $2.77M. The largest seller was Raymond James & Associates, cutting an estimated $2.94M.

  • 34 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q4 2022, up from 26 in Q3 2022.
  • Funds reported $22M of First Trust Nasdaq Pharmaceuticals ETF stock for Q4 2022, up 20% quarter-over-quarter.
  • 13 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q4 2022 and 4 closed out, a net change of +9 holders.
  • The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q4 2022 was Raymond James Financial Services Advisors, an estimated $2.77M added.
  • The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q4 2022 was Raymond James & Associates, an estimated $2.94M sold.

Based on aggregated 13F filings for Q4 2022.